Advanced SearchSearch Tips
Effects of SULT1A1 Copy Number Variation on Estrogen Concentration and Tamoxifen-Associated Adverse Drug Reactions in Premenopausal Thai Breast Cancer Patients: A Preliminary Study
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Effects of SULT1A1 Copy Number Variation on Estrogen Concentration and Tamoxifen-Associated Adverse Drug Reactions in Premenopausal Thai Breast Cancer Patients: A Preliminary Study
Charoenchokthavee, Wanaporn; Ayudhya, Duangchit Panomvana Na; Sriuranpong, Virote; Areepium, Nutthada;
  PDF(new window)
Tamoxifen is a pharmacological estrogen inhibitor that binds to the estrogen receptor (ER) in breast cells. However, it shows an estrogenic effect in other organs, which causes adverse drug reactions (ADRs). The sulfotransferase 1A1 (SULT1A1) enzyme encoded by the SULT1A1 gene is involved in estrogen metabolism. Previous research has suggested that the SULT1A1 copy number is linked with the plasma estradiol (E2) concentration. Here, a total of 34 premenopausal breast cancer patients, selected from the Thai Tamoxifen (TTAM) Project, were screened for their SULT1A1 copy number, plasma E2 concentration and ADRs. The mean age was , and they were subtyped as ER+/progesterone receptor (PR)+ (28 patients), ER+/PR- (5 patients) and ER-/PR- (1 patient). Three patients reported ADRs, which were irregular menstruation (2 patients) and vaginal discharge (1 patient). Most (33) patients had two SULT1A1 copies, with one patient having three copies. The median plasma E2 concentration was 1,575.6 (IQR 865.4) pg/ml. Patients with ADRs had significantly higher plasma E2 concentrations than those patients without ADRs (p
SULT1A1;copy number variations;adverse drug reaction;estrogen;tamoxifen;breast cancer;
 Cited by
Tamoxifen, Reactions Weekly, 2017, 1643, 1, 275  crossref(new windwow)
Berliere M, Duhoux FP, Dalenc F, et al (2013). Tamoxifen and ovarian function. PLoS ONE, 8, 66616. crossref(new window)

Del Re M, Michelucci A, Simi P, et al (2012). Pharmacogenetics of anti-estrogen treatment of breast cancer. Cancer Treat Rev, 38, 442-50. crossref(new window)

Dhingra K (1999). Antiestrogens-Tamoxifen, SERMs and Beyond. Invest New Drug, 17, 285-311. crossref(new window)

Dieudonne AS, Lambrechts D, Smeets D, et al (2014). The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen. Ann Oncol, 25, 90-5. crossref(new window)

Gjerde J, Geisler J, Lundgren S, et al (2010). Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer, 10, 313. crossref(new window)

Gjerde J, Hauglid M, Breilid H, et al (2008). Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol, 19, 56-61.

Kallstrom A, Salme R, Ryden L, et al (2010). $17{\beta}$-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer. Eur J Cancer, 46, 892-900. crossref(new window)

Kiyotani K, Mushiroda T, Imamura CK, et al (2012). Doseadjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat, 131, 137-45. crossref(new window)

Klein DJ, Thorn CF, Desta Z, et al (2013). PharmGKB summary: Tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics, 23, 643-7. crossref(new window)

Lonning P, Johannessen D, Lien E, et al (1995). Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol, 52, 491-6. crossref(new window)

Lorizio W, Wu AHB, Beattie MS, et al (2012). Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat, 132, 1107-18. crossref(new window)

Lum S, Woltering E, Fletcher W, et al (1997). Changes in serum estrogen levels in women during tamoxifen therapy. Am J Surg, 173, 399-402. crossref(new window)

Matsui S, Yasui T, Tani A, et al (2013). Associations of estrogen and testosterone with insulin resistance in pre- and postmenopausal women with and without hormone therapy. Int J Endocrinol Metab, 11, 65-70.

Moyer AM, Suman VJ, Weinshilboum RM, et al (2011). SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics, 12, 1535-43. crossref(new window)

Westbrook K, Stearns V (2013). Pharmacogenomics of breast cancer therapy: An update. Pharmacol Ther, 139, 1-11. crossref(new window)

Yang G, Nowsheen S, Aziz K, et al (2013). Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacol Ther, 139, 392-404. crossref(new window)

Yu X, Kubota T, Dhakal I, et al (2013). Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects. Pharmgenomics Pers Med, 6, 19-24.